For MZ SR:

  • director-General Department of Pharmacy and Drug Policy MUDr. Adam Hlôška
  • director of the Department of Classification, Pricing and Drug Policy PharmDr. Rastislav Pullmann
  • iVDr. Erika Hanzely
  • official of the Department of Legislation JUDr. Denis Lulko

For AstraZeneca AB:

  • MVDr. Ján Mikloš, Head of the organizational unit
  • Ing. Karolina Hoffmann

The meeting took place at the request of the company representatives AstraZeneca AB.
The meeting was opened by the Director General of the Department of Pharmacy and Drug Policy MUDr. Adam Dormouse.

AstraZeneca AB:

The list of categorised medicinal products contains 60 and 180- Duaklir dose pack. AstraZeneca submitted a request for decommissioning 180-dose pack from the list of categorised medicines, on 1.7.2016. The 60-dose supplement will be 16,1380%, AstraZeneca by extra charge the Board reduced to 11,3316%, i.e. the reimbursement to the original level.

MZ SR:

The Ministry must act only in accordance with the current legislation Law No 363/2011 and Decree No 435/2011.

The sitting was concluded by the Director General of the Pharmacy Section; and drug policy Dr Adam Hlôška

She wrote:
He checked for AstraZenec AB:
He approved:

Mr Erika Hanzely
Mr Ján Mikloš
Dr Adam Hlôška